Get the latest news alerts: at Twitter. Local Tech Wire RESEARCH TRIANGLE PARK, N.C. – Personal injury lawsuits against (NYSE: GSK) over the diabetes drug Avandia post a risk of up to $6 billion, according to analysts at UBS. The firm still rates GSK stock as a buy. However, The Associated Press and the U.K. Guardian both reported details of the UBS research note. () "Last week, in the wake of a critical Senate report on Avandia, the FDA is scrutinizing Avandia's cardiovascular risk profile. As US Avandia contributes 1% to sales, our concerns are solely on personal injury lawsuits," the UBS note written by Gbola Amusa said as quoted by the Guardian. "Experts we polled suggest Glaxo's liability is in the range of $1bn to $6bn. We expect liability below the midpoint of this range and note Glaxo has underperformed by around $2.5bn already."